Rare diseases are only rare if you don’t live with one. ®

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company. Our team is relentlessly focused on the development and commercialization of innovative therapeutic products for rare and orphan diseases.  

Quoin’s pipeline comprises three unique products that collectively have the potential to target a broad number of indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. We are committed to continuously expanding our pipeline of products to target additional rare and orphan diseases.

Our Lead Product: QRX003

QRX003 is a topical lotion that is currently being tested in two separate clinical trials as a potential treatment for Netherton Syndrome (NS).  

The product is a topical lotion formulated with a broad-spectrum serine protease inhibitor, which serves to replace the function of the LEKTI protein, which is absent in NS patients as a result of the mutation of the SPINK5 gene, and normalizes the rate of skin shedding, allowing for the formation of a properly functioning skin structure.  

The topical lotion has been formulated utilizing the proprietary Invisicare technology to be applied once daily to the surface of the skin. It dries quickly after application without leaving a sticky residue, doesn’t rub off or flake off after application and withstands repeat washing.  

About our clinical trials

● Trial 1 is a randomized, double blinded, vehicle-controlled study which is assessing two different doses of QRX003 topical lotion versus a vehicle lotion in 18 patients with NS. This is the first part of a registrational study and is currently only enrolling adult patients. After the first part of the study is completed, we will initiate the second part of the study which will open up to include both adult and pediatric patients.  

● Trial 2 is testing QRX003 in patients who are currently receiving off-label systemic therapy. Patients will remain on their systemic therapies for the duration of the study and will test QRX003 topical lotion in conjunction with the systemic therapy. This is an open-label study that is not vehicle-controlled and is currently enrolling adult patients.  

Patients are at the center of everything we do. We are committed to making our products available to every patient who needs them, everywhere.

For information about participating in our clinical trials, please visit www.NethertonSyndromeClinicalTrials.com or  for more information about current clinical trials, please visit www.clinicaltrials.gov.

Follow us on LinkedIn or Twitter. Or visit our website: www.quoinpharma.com